

### SANGOMA TECHNOLOGIES CORPORATION

Condensed consolidated interim financial statements for

### the three and six month periods ended December 31, 2022 and 2021

(Unaudited in thousands of US Dollars)

100 Renfrew Drive, Suite 100, Markham, Ontario, Canada L3R 9R6

# Sangoma Technologies Corporation December 31, 2022 and 2021

### Table of contents

| Condensed consolidated interim statements of financial position              | 3  |
|--|----|
| Condensed consolidated interim statements of loss and comprehensive loss     | 4  |
| Condensed consolidated interim statements of changes in shareholders' equity | 5  |
| Condensed consolidated interim statements of cash flows                      | 6  |
| Notes to the condensed consolidated interim financial statements7-           | 27 |

Condensed consolidated interim statements of financial position

As at December 31, 2022 and June 30, 2022

(Unaudited in thousands of US dollars, except per share data)

|   | December 31 | June 30    |
|---|-------------|------------|
|   | 2022        | 2022       |
| Assets  | \$          | ç          |
| Current assets  |             |            |
| Cash and cash equivalents (Note 4)                            | 6,799       | 12,702     |
| Trade and other receivables (Note 4, 20)                      | 22,511      | 23,943     |
| Inventories (Note 6)  | 19,297      | 17,426     |
| Income tax receivable   | 1,381       | 17,420     |
|   | -           | - 1 225    |
| Contract assets   | 1,494       | 1,225      |
| Derivative assets (Note 15)                                   | 1,245       | 648        |
| Other current assets  | 2,478       | 4,364      |
| Non-current assets  | 55,205      | 60,308     |
| Property and equipment (Note 7)                               | 10,088      | 10,274     |
| Right-of-use assets (Note 8)                                  | 15,003      | 16,974     |
| Intangible assets (Note 9)                                    | 174,214     | 191,369    |
| Development costs (Note 10)                                   | 5,546       | 2,861      |
| Deferred income tax assets                                    | 2,793       | 2,762      |
| Goodwill (Note 12)  | 210,009     | 210,009    |
| Contract assets   | 3,032       | 2,567      |
|   | -           |            |
| Derivative assets (Note 15)<br>Other non-current assets       | 984<br>668  | 700<br>709 |
| Other hon-current assets                                      | 477,542     | 498,533    |
|   | ,012        | 100,000    |
| Liabilities   |             |            |
| Current liabilities   |             |            |
| Accounts payable and accrued liabilities (Note 4)             | 23,819      | 28,568     |
| Provisions (Note 13)  | 212         | 200        |
| Sales tax payable   | 5,759       | 5,895      |
| Income tax payable  | -           | 1,885      |
| Consideration payable (Note 14)                               | 9,826       | 8,986      |
| Operating facility and loans (Note 15)                        | 17,700      | 17,700     |
| Contract liabilities (Note 16)                                | 10,693      | 11,580     |
| Lease obligations on right-of-use assets (Note 8)             | 3,133       | 3,592      |
|   | 71,142      | 78,406     |
| Long term liabilities   |             |            |
| Consideration payable (Note 14)                               | 1,362       | 3,782      |
| Operating facility and loans (Note 15)                        | 81,075      | 86,925     |
| Contract liabilities (Note 16)                                | 3,618       | 3,487      |
| Non-current lease obligations on right-of-use assets (Note 8) | 12,964      | 14,397     |
| Deferred income tax liabilities                               | 16,585      | 16,657     |
| Other non-current liabilities                                 | 995         | 1,071      |
|   | 187,741     | 204,725    |
| Shareholders' equity  |             |            |
| Share capital   | 228,727     | 203,032    |
| Shares to be issued   | 151,315     | 179,132    |
| Contributed surplus   | 17,232      | 15,055     |
| Accumulated other comprehensive income                        | 1,488       | 839        |
| Deficit   | (108,961)   | (104,250   |
|   |             |            |
| Dencit  | 289,801     | 293,808    |

Approved by the Board

(Signed) Al Guarino Director

(Signed) Allan Brett Director

Condensed consolidated interim statements of loss and comprehensive loss For the three and six month periods ended December 31, 2022 and 2021

(Unaudited in thousands of US dollars, except per share data)

|  | Three month periods ended |    | Six month periods ended |               |     |          |
|--|---------------------------|----|-------------------------|---------------|-----|----------|
|  | December 31               |    | Dece                    | mber 3        | 1   |          |
|  | <br>2022                  |    | 2021                    | 2022          |     | 2021     |
|  |                           |    | (Note 2)                |               |     | (Note 2) |
|  | \$                        |    | \$                      | \$            |     | \$       |
| Revenue (Note 19)  | 62,035                    |    | 53,186                  | 126,086       |     | 104,685  |
| Cost of sales  | 19,246                    |    | 14,833                  | 39,960        |     | 29,459   |
| Gross profit   | 42,789                    |    | 38,353                  | 86,126        |     | 75,226   |
| Expenses   |                           |    |                         |               |     |          |
| Sales and marketing  | 15,613                    |    | 13,195                  | 31,261        |     | 25,302   |
| Research and development   | 9,227                     |    | 7,759                   | 18,656        |     | 16,119   |
| General and administration   | 19,518                    |    | 18,148                  | 38,811        |     | 35,415   |
| Foreign currency exchange (gain) loss                                  | (100)                     |    | 92                      | (64)          |     | 85       |
|  | 44,258                    |    | 39,194                  | 88,664        |     | 76,921   |
| Loss before interest expense (net), business integration costs,        | ,200                      |    | 00,101                  |               |     |          |
| gain on change in fair value of consideration payable                  |                           |    |                         |               |     |          |
| and income taxes   | (1,469)                   |    | (841)                   | (2,538)       |     | (1,695)  |
|  | (1,111)                   |    | (•••)                   | (_,)          |     | (1,222)  |
| Interest expense (net) (Notes 4, 8, 14, 15)                            | 1,632                     |    | 597                     | 3,210         |     | 1,253    |
| Business integration costs   | 355                       |    | -                       | 407           |     | 836      |
| Exchange listing expense   | -                         |    | 1,051                   | -             |     | 1,051    |
| (Gain) loss on change in fair value of consideration payable (Note 14) | (350)                     |    | (143)                   | (1,931)       |     | 104      |
|  | 1,637                     |    | 1,505                   | 1,686         |     | 3,244    |
| Loss before income tax   | (3,106)                   |    | (2,346)                 | (4,224)       |     | (4,939)  |
| Provision for (recovery of) income taxes                               | (0,100)                   |    | (2,040)                 | (4,224)       |     | (4,000)  |
| Current (Note 11)  | 744                       |    | 438                     | 785           |     | 808      |
| Deferred (Note 11)   | (1,115)                   |    | (307)                   | (298)         |     | (969)    |
| Net loss   | (2,735)                   |    | (2,477)                 | (4,711)       |     | (4,778)  |
|  | (_,,                      |    | (=,)                    | (.,)          |     | (1,110)  |
| Other comprehensive income (loss)                                      |                           |    |                         |               |     |          |
| Items to be reclassified to net income (loss)                          |                           |    |                         |               |     |          |
| Change in fair value of interest rate                                  |                           |    | 110                     |               |     | 454      |
| swaps, net of tax (Note 15)  | 212                       |    | 112                     | 649           |     | 151      |
| Comprehensive loss   | (2,523)                   |    | (2,365)                 | (4,062)       |     | (4,627)  |
| Loss per share   |                           |    |                         |               |     |          |
| Basic (Note 17(iii))   | \$<br>(0.084)             | \$ | (0.078)                 | \$<br>(0.143) | \$  | (0.151)  |
| Diluted (Note 17(iii))   | \$<br>(0.084)             | \$ | (0.078)                 | \$<br>(0.143) | \$  | (0.151)  |
| Weighted average number  |                           |    |                         |               |     |          |
| of shares outstanding (Note 17(iii))                                   |                           |    |                         |               |     |          |
| Basic  | 32,512,058                |    | 31,726,308              | 33,039,477    | 31. | 721,761  |
| Diluted  | 32,512,058                |    | 31,726,308              | 33,039,477    | ,   | 721,761  |
| Diluco   | 52,512,030                |    | 01,720,000              | 55,053,477    | 51, | 121,101  |

**Sangoma Technologies Corporation** Condensed consolidated interim statements of changes in shareholders' equity For the six month periods ended December 31, 2022 and 2021

(Unaudited in thousands of US dollars, except per share data)

|  | Number of  |         | Shares   |             | Accumulated other |                    | Total        |
|--|------------|---------|----------|-------------|-------------------|--------------------|--------------|
|  | common     | Share   | to be    | Contributed | comprehensive     | Retained           | shareholders |
|  | shares     | capital | issued   | surplus     | income (loss)     | earnings (deficit) | equity       |
|  |            | \$      | \$       | \$          | \$                | \$                 | \$           |
| Balance, July 1, 2021                                  | 19,021,642 | 172,462 | 192,102  | 5,393       | (333)             | 6,530              | 376,154      |
| Net loss   | -          | -       | -        | -           | -                 | (4,778)            | (4,778)      |
| Change in fair value of interest rate swaps,           |            |         |          |             |                   |                    |              |
| net of tax (Note 15)                                   | -          | -       | -        | -           | 151               | -                  | 151          |
| Deferred tax benefit on share issuance costs (Note 11) | -          | 138     | -        | -           | -                 | -                  | 138          |
| Common shares issued                                   |            |         |          |             |                   |                    |              |
| for options exercised (Note 17(i))                     | 39,594     | 524     | -        | (178)       | -                 | -                  | 346          |
| Rounding of fractional shares                          |            |         |          |             |                   |                    |              |
| after share consolidation                              | (28)       | -       | -        | -           | -                 | -                  | -            |
| Share-based compensation expense (Note 17(ii))         | -          | -       | -        | 4,452       | -                 | -                  | 4,452        |
| Balance, December 31 2021                              | 19,061,208 | 173,124 | 192,102  | 9,667       | (182)             | 1,752              | 376,463      |
| Balance, July 1, 2022                                  | 21,439,632 | 203,032 | 179,132  | 15,055      | 839               | (104,250)          | 293,808      |
| Net loss   | -          | -       | -        | -           | -                 | (4,711)            | (4,711)      |
| Change in fair value of interest rate swaps,           |            |         |          |             |                   |                    |              |
| net of tax (Note 15)                                   | -          | -       | -        | -           | 649               | -                  | 649          |
| Common shares issued                                   |            |         |          |             |                   |                    |              |
| as instalment for shares to be issued (Note 17(i))     | 1,838,458  | 27,817  | (27,817) |             |                   |                    | -            |
| Common shares issued                                   |            |         |          |             |                   |                    |              |
| for options exercised (Note 17(i))                     | 9,234      | 57      | -        | (20)        | -                 | -                  | 37           |
| Common shares  |            |         |          |             |                   |                    |              |
| purchased and cancelled (Note 17(i))                   | (78,822)   | (477)   | -        | -           | -                 | -                  | (477)        |
| Common shares  |            |         |          |             |                   |                    |              |
| returned from escrow (Note 4)                          | (142,124)  | (1,702) | -        | -           | -                 | -                  | (1,702)      |
| Share-based compensation expense (Note 17(ii))         | -          | -       | -        | 2,197       | -                 | -                  | 2,197        |
| Balance, December 31, 2022                             | 23,066,378 | 228,727 | 151,315  | 17,232      | 1,488             | (108,961)          | 289,801      |

### Sangoma Technologies Corporation Condensed consolidated interim statements of cash flows

Condensed consolidated interim statements of cash flows For the six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

|  | Six month periods ende |         |
|--|------------------------|---------|
|  | Decer                  | mber 31 |
|  | 2022                   | 2021    |
| Operating activities   | \$                     | \$      |
| Net loss   | (4,711)                | (4,778) |
| Adjustments for:   |                        |         |
| Depreciation of property and equipment (Note 7)                          | 2,499                  | 984     |
| Depreciation of right-of-use assets (Note 8)                             | 1,978                  | 1,486   |
| Amortization of intangible assets (Note 9)                               | 17,155                 | 15,299  |
| Amortization of development costs (Note 10)                              | 1,024                  | 515     |
| Income tax expense (Note 11)   | 487                    | (969)   |
| Income tax paid  | (3,946)                | (1,633  |
| Share-based compensation expense (Note 17(ii))                           | 2,197                  | 4,452   |
| Interest on obligation on right-of-use assets (Note 8)                   | 252                    | 217     |
| Unrealized foreign exchange gain (loss)                                  | 150                    | 44      |
| Accretion expense (Note 14)  | 351                    | -       |
| Gain on lease modification (Note 8)                                      | (36)                   | -       |
| Loss on disposal of property and equipment (Note 7)                      | 158                    | -       |
| (Gain) loss on change in fair value of consideration payable (Note 14)   | (1,931)                | 104     |
| Changes in working capital   |                        |         |
| Trade receivables  | (620)                  | (1,240) |
| Inventories  | (1,871)                | (2,521) |
| Income tax receivable  | -                      | 1,992   |
| Contract assets  | (734)                  | (1,101) |
| Other assets   | 1,927                  | (2,223) |
| Sales tax payable  | (136)                  | (373)   |
| Accounts payable and accrued liabilities                                 | (4,749)                | (1,465) |
| Provisions   | 12                     | (159)   |
| Other non current liabilites   | (76)                   | -       |
| Contract liabilities   | (756)                  | (1,977) |
| Net cash flows from operating activities                                 | 8,624                  | 6,654   |
| Investing activities   |                        |         |
| Purchase of property and equipment (Note 7)                              | (2,471)                | (509)   |
| Development costs (Note 10)  | (3,647)                | (736)   |
| Business combinations, net of cash and cash                              |                        | (0.000) |
| equivalents acquired (Note 20)   | -                      | (2,000) |
| Net cash flows used in investing activities                              | (6,118)                | (3,245) |
| Financing activities   |                        |         |
| Proceeds from operating facility and loan (Note 15)                      | 3,000                  | -       |
| Repayments of operating facility and loan (Note 15)                      | (8,850)                | (7,276) |
| Repayment of right-of-use lease obligation (Note 8)                      | (2,119)                | (1,623) |
| Common shares purchased and cancelled (Note 17(i))                       | (477)                  | -       |
| Issuance of common shares for stock options exercised (net) (Note 17(i)) | 37                     | 347     |
| Net cash flows used in financing activities                              | (8,409)                | (8,552) |
| Decrease in cash and cash equivalents                                    | (5,903)                | (5,143) |
| Cash and cash equivalents, beginning of the period                       | 12,702                 | 22,096  |
| Cash and cash equivalents, end of the period                             | 6,799                  | 16,953  |

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

#### 1. General information

Founded in 1984, Sangoma Technologies Corporation ("Sangoma" or the "Company") is publicly traded on the Toronto Stock Exchange (TSX: STC) and NASDAQ (NASDAQ: SANG). The Company's shares were traded on the TSX Venture Exchange under the symbol STC until November 1, 2021, at which point the Company's shares commenced trading on the TSX. In conjunction with listing on the TSX, the Company's shares were delisted from the TSX Venture Exchange. The Company's shares commenced trading on NASDAQ on December 16, 2021. The Company was incorporated in Canada, its legal name is Sangoma Technologies Corporation and its primary operating subsidiaries for fiscal 2023 are Sangoma Technologies Inc., Sangoma US Inc., VoIP Supply LLC, Digium Inc., VoIP Innovations LLC, Star2Star Communications LLC, and NetFortris Corporation.

Sangoma is a leading provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. Enterprises, small to medium sized businesses ("SMBs") and telecom operators in over 150 countries rely on Sangoma's technology as part of their mission critical infrastructures. The product line includes data and telecom boards for media and signal processing, as well as gateway appliances and software.

The Company is domiciled in Ontario, Canada. The address of the Company's registered office is 100 Renfrew Dr., Suite 100, Markham, Ontario, L3R 9R6 and the Company operates in multiple jurisdictions.

#### 2. Significant accounting policies

#### Statement of compliance and basis of presentation

These interim financial statements for the three and six month periods ended December 31, 2022 and 2021 have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB").

These interim financial statements do not include all of the disclosures required by International Financial Reporting Standards ("IFRS") for annual consolidated financial statements and accordingly should be read in conjunction with the Company's audited consolidated financial statements for the year ended June 30, 2022 ("annual financial statements") prepared in accordance with IFRS as issued by the IASB.

During the fourth quarter ended June 30, 2022, the Company identified an inconsistency in its treatment of certain revenues being recorded gross versus net. As a result, the Company corrected the presentation of revenue in its annual consolidated financial statements for the year ended June 30, 2022. As indicated in our management discussion & analysis for the fourth quarter ended June 30, 2022 (the "Fiscal 2022 MD&A"), the impacts of these changes to each quarter of fiscal 2022 were not material. In these unaudited condensed consolidated interim financial statements, the comparative periods have been reclassified for these changes. As a result, revenue, gross margin and sales and marketing expense have been reduced by \$1,050 and \$2,030 in the three and six month periods ended December 31, 2021 as compared to amounts previously reported. The impact of this change had no impact on net loss or cash flow from operations for the comparative periods.

The condensed consolidated interim financial statements were authorized for issue by the Board of Directors on February 9, 2023.

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

### 3. Significant accounting judgments, estimates and uncertainties

These unaudited condensed consolidated interim financial statements were prepared using the same basis of presentation, accounting policies and methods of computation as those of the audited consolidated financial statements for the year ended June 30, 2022. They were prepared using the same critical estimates and judgments in applying the accounting policies as those of the audited consolidated financial statements for the year ended June 30, 2022, except for the following which are new in 2022.

On December 13, 2022, the Company adopted the Omnibus Equity Incentive Plan (the "Plan"). Under the Plan, the Company may grant participants Options, Performance Share Units (PSUs), Restricted Share Units (RSUs) and Deferred Share Units (DSUs). The PSUs, RSUs and DSUs are redeemable either for one common share or for an amount in cash equal to the fair market value of one common share (at the option of the Company and as set out in the participant's equity award agreement). All PSUs, RSUs and DSUs are accounted for as equity-settled awards.

DSUs generally vest immediately and become redeemable once a director no one longer serves on the board of the Company. RSUs vest over a three-year period after the date of grant. The expense is measured based on the fair value of the awards at the grant date.

PSUs vest in full at the end of a three-year period and the final amount is based 50% on market-based performance targets being met and 50% on non-market-based performance targets, with the conversion ratio for vested PSUs being from 0% to 150%. The expense related to the PSUs is measured (i) based on the fair value of the awards at the grant date using the Monte Carlo simulation, with respect to the 50% based on the market-based performance targets, and (ii) based on the fair value of the awards at the grant date using price per share on the TSX during the immediately preceding five trading days.

The preparation of the interim financial statements requires Management to make judgments, estimates and assumptions that affect the application of accounting policies and reported assets, liabilities, revenue and expenses, consistent with those described in the Company's annual financial statements and as described in these interim financial statements. Estimates and underlying assumptions are reviewed on an ongoing basis. Estimates are based on historical experience and other assumptions that are considered reasonable in the circumstances. The actual amount or values may vary in certain instances from the assumptions and estimates made. Changes will be recorded, with the corresponding effect on profit or loss, when, and if, better information is obtained.

### 4. Financial instruments

The fair values of the cash and cash equivalents, trade and other receivables, derivative assets, contract assets, other current assets, accounts payable and accrued liabilities, consideration payable and derivative liabilities approximate their carrying values due to the relatively short-term nature of these financial instruments or as these financial instruments are fair valued at each reporting period. The fair values of operating facility and loans approximate their carrying values due to variable interest loans or fixed rate loan, which represent market rate.

Cash and cash equivalents are comprised of:

|                          | December 31 | June 30 |
|--------------------------|-------------|---------|
|                          | 2022        | 2022    |
|                          | \$          | \$      |
| Cash at bank and on hand | 6,799       | 12,702  |

Cash includes demand deposits with financial institutions and cash equivalents consist of short-term, highly liquid investments purchased with original maturities of three months or less. As at December 31, 2022 and June 30, 2022 the Company had no cash equivalents.

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

#### 4. Financial instruments

Total interest income and interest expense for financial assets or financial liabilities that are not at fair value through profit or loss can be summarized as follows:

|                                 | Three month periods ended<br>December 31 |     | Six month pe<br>Dece | riods ended<br>ember 31 |
|---------------------------------|--|-----|----------------------|-------------------------|
|                                 | <b>2022</b> 2021                         |     | 2022                 | 2021                    |
|                                 | \$                                       | \$  | \$                   | \$                      |
| Interest income                 | (30)                                     | -   | (30)                 | -                       |
| Interest expense (Note 15)      | 1,363                                    | 500 | 2,638                | 1,036                   |
| Accretion expense (Notes 8, 14) | 299                                      | 97  | 602                  | 217                     |
| Interest expense (net)          | 1,632                                    | 597 | 3,210                | 1,253                   |

The Company examines the various financial instrument risks to which it is exposed and assesses the impact and likelihood of those risks. These risks may include credit risk, liquidity risk, foreign currency risk, interest rate risk and market risk.

#### Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its obligations. Where possible, the Company uses an insurance policy with Export Development Canada ("EDC") for its trade receivables to manage this risk and minimize any exposure.

|  | December 31 | June 30 |
|--|-------------|---------|
|  | 2022        | 2022    |
|  | \$          | \$      |
| Trade receivables  | 16,665      | 16,045  |
| Receivable related to working capital adjustment (Note 20) | 5,846       | 7,898   |
| Trade and other receivables                                | 22,511      | 23,943  |

During the period ended December 31, 2022, the parties finalized the working capital provision in respect of the acquisition of NetFortris and the company received \$2,052 from the escrow account, consisting of \$350 in cash and \$1,702 in the form of 142,124 common shares. The remaining balance of \$5,846 as at December 31, 2022 relates to certain indemnification assets recorded in respect of liabilities assumed on the acquisition of Netfortris. (June 30, 2022-\$7,898)

The Company's maximum exposure to credit risk for its trade receivables is summarized as follows with some of the over 90-day receivable not being covered by EDC:

|                                       | December 31 | June 30 |
|---------------------------------------|-------------|---------|
|                                       | 2022        | 2022    |
|                                       | \$          | \$      |
| Trade receivables aging:              |             |         |
| 0-30 days                             | 12,077      | 12,809  |
| 31-90 days                            | 3,416       | 2,541   |
| Greater than 90 days                  | 3,555       | 2,976   |
|                                       | 19,048      | 18,326  |
| Expected credit loss provision        | (2,383)     | (2,281) |
| · · · · · · · · · · · · · · · · · · · | 16,665      | 16,045  |

The movement in the provision for expected credit losses can be reconciled as follows:

|  | December 31 |         |
|--|-------------|---------|
|  | 2022        | 2022    |
|  | \$          | \$      |
| Expected credit loss provision:                                |             |         |
| Expected credit loss provision, beginning balance              | (2,281)     | (1,096) |
| Net change in expected credit loss provision during the period | (102)       | (1,185) |
| Expected credit loss provision, ending balance                 | (2,383)     | (2,281) |

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

#### 4. Financial instruments

The Company applies the simplified approach to provide for expected credit losses as prescribed by IFRS 9, which permits the use of the lifetime expected loss provision for all trade receivables and contract assets. The expected credit loss provision is based on the Company's historical collections and loss experience and incorporates forward-looking factors, where appropriate.

Substantially all of the Company's cash and cash equivalents are held with major Canadian or US financial institutions and thus the exposure to credit risk is considered insignificant. Management actively monitors the Company's exposure to credit risk under its financial instruments, including with respect to trade receivables.

#### Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its obligations associated with financial liabilities. The Company has a planning and budgeting process in place by which it anticipates and determines the funds required to support its normal operating requirements. The Company coordinates this planning and budgeting process with its financing activities through its capital management process.

The Company holds sufficient cash and cash equivalents and working capital, maintained through stringent cash flow management, to ensure sufficient liquidity is maintained. The following are the undiscounted contractual maturities of significant financial liabilities of the Company as at December 31, 2022:

|  | within 12 months | 12-24 months | 24-36 months | >36 months | Tota    |
|--|------------------|--------------|--------------|------------|---------|
|  | \$               | \$           | \$           | \$         | 9       |
| Accounts payable and accrued liabilities | 23,819           | -            | -            | -          | 23,819  |
| Sales tax payable                        | 5,759            | -            | -            | -          | 5,759   |
| Consideration payable                    | 10,252           | 627          | 627          | 261        | 11,767  |
| Operating facility and loans             | 17,700           | 17,700       | 22,775       | 40,600     | 98,775  |
| Lease obligations on right of use assets | 3,556            | 3,101        | 2,716        | 8,458      | 17,831  |
| Other non-current liabilities            | -                | -            | -            | 995        | 995     |
|  | 61,086           | 21,428       | 26,118       | 50,314     | 158,946 |

#### Foreign currency risk

A portion of the Company's transactions occur in a foreign currency (Canadian Dollars (CAD), Euros (EUR), and Great British Pounds (GBP), Hong Kong Dollars (HKD), Indian Rupees (INR), Philippine Peso (PHP), Australian Dollar (AUD)) and, therefore, the Company is exposed to foreign currency risk at the end of the reporting period through its foreign denominated cash, trade receivables, contract assets, accounts payable and accrued liabilities, and operating facility and loans. As at December 31, 2022, a 10% depreciation or appreciation of the CAD, EUR, GBP, HKD, INR, PHP, and AUD currencies against the U.S. dollar would have resulted in an approximate \$71 (June 30, 2022 - \$59) increase or decrease, respectively, in total comprehensive loss.

### Interest rate risk

The Company's exposure to interest rate fluctuations is with its credit facility (Note 15) which bears interest at a floating rate. As at December 31, 2022, a change in the interest rate of 1% per annum would have an impact of approximately \$463 (December 31, 2021 - \$568) per annum in finance costs. The Company also entered an interest rate swap arrangement for its loan facility (Note 15) to manage the exposure to changes in LIBOR-rate based interest rate. The fair value of the interest rate swaps was estimated based on the present value of projected future cash flows using the LIBOR forward rate curve. The model used to value the interest rate swaps included inputs of readily observable market data, a Level 2 input. As described in detail in Note 15, the fair value of the interest rate swaps was a current asset of \$1,245 and non-current asset of \$984 on December 31, 2022 (June 30, 2022- current asset \$648 and non-current asset of \$700).

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

#### 5. Capital management

The Company's objectives in managing capital are to safeguard the Company's assets, to ensure sufficient liquidity to sustain the future development of the business via advancement of its significant research and development efforts, to conservatively manage financial risk and to maximize investor, creditor, and market confidence. The Company considers its capital structure to include its shareholders' equity and operating facilities and loans. Working capital is optimized via stringent cash flow policies surrounding disbursement, foreign currency exchange and investment decision-making. There have been no changes in the Company's approach to capital management during the year and apart from the financial covenants as discussed in Note 15, the Company is not subject to any other capital requirements imposed by external parties.

### 6. Inventories

Inventories recognized in the condensed consolidated interim statements of financial position are comprised of:

|                              | December 31 | June 30 |
|------------------------------|-------------|---------|
|                              | 2022        | 2022    |
|                              | \$          | \$      |
| Finished goods               | 14,924      | 13,190  |
| Parts                        | 5,353       | 5,155   |
|                              | 20,277      | 18,345  |
| Provision for obsolescence   | (980)       | (919)   |
| Net inventory carrying value | 19,297      | 17,426  |

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

#### 7. Property and equipment

|   | Office furniture<br>and computer<br>equipment | Software and<br>books | Stockroom<br>and production<br>equipment | Tradeshow<br>equipment | Leasehold<br>improvements | Total  |
|---|---|-----------------------|--|------------------------|---------------------------|--------|
| Cost  | \$  | \$                    | \$                                       | \$                     | \$                        | \$     |
| Balance at July 1, 2021                           | 3,329   | 417                   | 6,255                                    | 47                     | 348                       | 10,396 |
| Additions through business combinations (Note 20) | 540   | 2                     | 3,619                                    | -                      | 11                        | 4,172  |
| Additions   | 893   | 41                    | 808                                      | -                      | 126                       | 1,868  |
| Disposals   | (25)  | (2)                   | (231)                                    | -                      | (10)                      | (268)  |
| Balance at June 30, 2022                          | 4,737   | 458                   | 10,451                                   | 47                     | 475                       | 16,168 |
| Additions   | 541   | -                     | 1,930                                    | -                      | -                         | 2,471  |
| Disposals   | (2)   | -                     | (156)                                    | -                      | -                         | (158)  |
| Balance at December 31, 2022                      | 5,276   | 458                   | 12,225                                   | 47                     | 475                       | 18,481 |
| Accumulated depreciation                          |   |                       |  |                        |                           |        |
| Balance at July 1, 2021                           | 1,371   | 314                   | 872                                      | 41                     | 146                       | 2,744  |
| Depreciation expense                              | 1,081   | 99                    | 1,888                                    | 6                      | 78                        | 3,152  |
| Disposals   | -   | -                     | (1)                                      | -                      | (1)                       | (2)    |
| Balance at June 30, 2022                          | 2,452   | 413                   | 2,759                                    | 47                     | 223                       | 5,894  |
| Depreciation expense                              | 582   | 10                    | 1,875                                    | -                      | 32                        | 2,499  |
| Balance at December 31, 2022                      | 3,034   | 423                   | 4,634                                    | 47                     | 255                       | 8,393  |
| Net book value as at:                             |   |                       |  |                        |                           |        |
| Balance at June 30, 2022                          | 2,285   | 45                    | 7,692                                    | -                      | 252                       | 10,274 |
| Balance at December 31, 2022                      | 2,242   | 35                    | 7,591                                    | -                      | 220                       | 10,088 |

For the three and six month periods ended December 31, 2022, depreciation expenses of \$261 and \$524 (three and six month periods ended December 31, 2021 - \$247 and \$496) were recorded in general and administration expense in the condensed consolidated interim statements of loss and comprehensive loss. Depreciation expenses in the amounts of \$932 and \$1,975 were included in cost of sales for the three and six month periods ended December 31, 2021 - \$247 and \$496).

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

### 8. Leases: Right-of-use assets and lease obligations

The Company's lease obligations and right-of-use assets are presented below:

|   | Right-of-use assets |
|---|---------------------|
|   | \$                  |
| Balance at July 1, 2021                         | 17,955              |
| Additions                                       | 5,536               |
| Addition through business combination (Note 20) | 3,277               |
| Terminations                                    | (1,536)             |
| Adjustments due to lease modification           | (2,002)             |
| Balance at June 30, 2022                        | 23,230              |
| Additions                                       | 41                  |
| Terminations                                    | (280)               |
| Balance at December 31, 2022                    | 22,991              |
| Accumulated depreciation and repayments         |                     |
| Balance at July 1, 2021                         | 4,425               |
| Depreciation expense                            | 3,308               |
| Terminations                                    | (1,477)             |
| Balance at June 30, 2022                        | 6,256               |
| Depreciation expense                            | 1,978               |
| Terminations                                    | (246)               |
| Balance at December 31, 2022                    | 7,988               |
| Net book value as at:                           |                     |
| June 30, 2022                                   | 16,974              |
| December 31, 2022                               | 15,003              |

|   | Lease Obligations |
|---|-------------------|
|   | \$                |
| Balance at July 1, 2021                         | 14,243            |
| Additions                                       | 5,535             |
| Addition through business combination (Note 20) | 3,277             |
| Adjustments due to lease modification           | (2,107)           |
| Repayments                                      | (3,407)           |
| Accretion expense                               | 442               |
| Effects of movements on exchange rates          | 6                 |
| Balance at June 30, 2022                        | 17,989            |
| Additions                                       | 41                |
| Adjustments due to lease modification           | (36)              |
| Repayments                                      | (2,119)           |
| Accretion expense                               | 252               |
| Effects of movements on exchange rates          | (30)              |
| Balance at December 31, 2022                    | 16,097            |
| Lease Obligations - Current                     | 3,133             |
| Lease Obligations - Non-current                 | 12,964            |
|   | 16,097            |

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

### 9. Intangible assets

|                                 |            |               |       | Other       |         |
|---------------------------------|------------|---------------|-------|-------------|---------|
|                                 | Purchased  | Customer      |       | purchased   |         |
|                                 | technology | relationships | Brand | intangibles | Total   |
|                                 | \$         | \$            | \$    | \$          | \$      |
| Cost                            |            |               |       |             |         |
| Balance at July 1, 2021         | 95,323     | 112,256       | 6,787 | 2,748       | 217,114 |
| Business combinations (Note 20) | 14,800     | 14,200        | -     | -           | 29,000  |
| Balance at June 30, 2022        | 110,123    | 126,456       | 6,787 | 2,748       | 246,114 |
| Balance at December 31, 2022    | 110,123    | 126,456       | 6,787 | 2,748       | 246,114 |
| Accumulated amortization        |            |               |       |             |         |
| Balance at July 1, 2021         | 7,809      | 11,336        | 2,135 | 1,856       | 23,136  |
| Amortization expense            | 16,097     | 14,128        | 685   | 699         | 31,609  |
| Balance at June 30, 2022        | 23,906     | 25,464        | 2,820 | 2,555       | 54,745  |
| Amortization expense            | 8,903      | 7,774         | 405   | 73          | 17,155  |
| Balance at December 31, 2022    | 32,809     | 33,238        | 3,225 | 2,628       | 71,900  |
| Net book value as at:           |            |               |       |             |         |
| Balance at June 30, 2022        | 86,217     | 100,992       | 3,967 | 193         | 191,369 |
| Balance at December 31, 2022    | 77,314     | 93,218        | 3,562 | 120         | 174,214 |

Amortization expense is included in general and administration expense in the consolidated interim statements of loss and comprehensive loss. For the three and six month periods ended December 31, 2022, amortization expenses were \$8,578 and \$17,155 (three and six month periods ended December 31, 2021 - \$7,644 and \$15,298).

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

### 10. Development costs

| Cost                              |                   | \$            |
|-----------------------------------|-------------------|---------------|
| Balance at July 1, 2021           |                   | 3,360         |
| Additions                         |                   | 3,237         |
| Investment tax credits            |                   | (628)         |
| Balance at June 30, 2022          |                   | 5,969         |
| Additions                         |                   | 3,647         |
| Investment tax credits            |                   | 62            |
| Balance at December 31, 2022      |                   | 9,678         |
| Accumulated amortization          |                   |               |
| Balance at July 1, 2021           |                   | (1,827)       |
| Amortization                      |                   | (1,281)       |
| Balance at June 30, 2022          |                   | (3,108)       |
| Amortization                      |                   | (1,024)       |
| Balance at December 31, 2022      |                   | (4,132)       |
|                                   | December 31, 2022 | June 30, 2022 |
|                                   | \$                | \$            |
| Net capitalized development costs | 5,546             | 2,861         |

Each period, additions to development costs are recognized net of investment tax credits accrued. In addition to the above amortization, the Company has recognized \$8,625 and \$17,632 of engineering expenditures as expenses during the three and six month periods ended December 31, 2022 (three and six month periods ended December 31, 2021 - \$7,419 and \$15,604).

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

#### 11. Income tax

The Company income tax expense is determined as follows:

|   | Three month per | iods ended  | Six month per | iods ended  |  |
|---|-----------------|-------------|---------------|-------------|--|
|   | Decen           | December 31 |               | December 31 |  |
|   | 2022            | 2021        | 2022          | 2021        |  |
| Statutory income tax rate                                 | 26.15%          | 26.37%      | 26.15%        | 26.37%      |  |
|   | \$              | \$          | \$            | \$          |  |
| Net loss before income taxes                              | (3,106)         | (2,346)     | (4,224)       | (4,939)     |  |
| Expected income tax expense                               | (812)           | (619)       | (1,104)       | (1,302)     |  |
| Difference in foreign tax rates                           | (1)             | 17          | (10)          | 10          |  |
| Share based compensation                                  | 335             | 579         | 574           | 1,174       |  |
| Other non deductible expenses                             | (52)            | 23          | (33)          | 44          |  |
| Change in estimates                                       | 23              | (23)        | 23            | (23)        |  |
| Scientific Research and Experimental Development (SR&ED)  | 36              | -           | 36            | -           |  |
| Sec 481(a) adjustment                                     | (34)            | -           | -             | -           |  |
| Gain on consideration payable                             | (92)            | (35)        | (506)         | 26          |  |
| Stock options deduction revaluation adjustment            | 183             | 180         | 1,350         | (99)        |  |
| Earn-out amortization                                     | 46              | -           | 92            | -           |  |
| Changes in tax benefits not recognized                    | (3)             | 9           | 65            | 9           |  |
| Income tax expense  | (371)           | 131         | 487           | (161)       |  |
| The Company's income tax expense is allocated as follows: | \$              | \$          | \$            | \$          |  |
| Current tax expense                                       | 744             | 438         | 785           | 808         |  |
| Deferred income tax expense                               | (1,115)         | (307)       | (298)         | (969)       |  |
| Income tax expense  | (371)           | 131         | 487           | (161)       |  |

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

### 12. Goodwill

The carrying amount and movements of goodwill was as follows:

|  | \$       |
|--|----------|
| Balance at July 1, 2021                          | 267,398  |
| Addition through business combinations (Note 20) | 34,296   |
| Goodwill Impairment                              | (91,685) |
| Balance at June 30, 2022                         | 210,009  |
| Balance at December 31, 2022                     | 210,009  |

For the three and six month periods ended December 31, 2022, there is no addition to goodwill. The company has evaluated for triggers of impairment at December 31, 2022 and has not identified any impairment.

### 13. Provisions

|  | Warranty<br>provision | Sales returns<br>& allowances<br>provision | Stock<br>rotation<br>provision | Total |
|--|-----------------------|--|--------------------------------|-------|
|  | \$                    | \$   | \$                             | \$    |
| Balance at July 1, 2021                    | 241                   | 175  | 26                             | 442   |
| Additional provision recognized (reversed) | (168)                 | (48)                                       | (26)                           | (242) |
| Balance at June 30, 2022                   | 73                    | 127  | -                              | 200   |
| Additional provision recognized (reversed) | (2)                   | (89)                                       | 103                            | 12    |
| Balance at December 31, 2022               | 71                    | 38   | 103                            | 212   |

The provision for warranty obligations represents the Company's best estimate of repair and/or replacement costs to correct product failures. The sales returns and allowances provision represent the Company's best estimate of the value of the products sold in the current financial period that may be returned in a future period. The stock rotation provision represents the Company's best estimate of the value of the products sold in the current financial period that may be returned in a future period. The stock rotation provision represents the Company's best estimate of the value of the products sold in the current financial period that may be exchanged for alternative products in a future period. The Company accrues for product warranties, stock rotation, and sales returns and allowances at the time the product is delivered.

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

### 14. Consideration payable

As described in the annual consolidated financial statements, additional consideration in the amount of \$13,269 could be payable as part of the acquisition of Star2Star on March 31, 2021. The fair value of consideration payable as of December 31, 2022 in the amount of \$4,204 (June 30, 2022 - \$6,017) was determined using an effective tax rate of 26.22% (June 30, 2022 – 26.22%) and a discount rate of 4.9% (June 30, 2022 – 4.9%). The fair value of the consideration payable is dependent upon the Company's share price, foreign exchange rates and the Company's ability to utilize the underlying tax losses as they become available in each reporting period. During the period ended December 31, 2022, the Company made payments of \$nil (December 31, 2021-\$nil). For the three and six month periods ended December 31, 2022, the company recognized accretion expense of \$59 and \$118 (three and six month periods ended December 31, 2021-\$nil), and recognized a gain on change in fair value of \$350 and \$1,931 (three and six month periods ended December 31, 2021 – gain of \$143 and loss of \$104).

As described in Note 20, additional consideration of up to \$11,500 could be payable as part of the acquisition of NetFortris Corporation. The fair value of consideration payable as of December 31, 2022 in the amount of \$6,984 (June 30, 2022-\$6,751) was determined using a discount rate of 13.0% (June 30, 2022-13.0%). The fair value of the consideration payable is dependent upon the Company's ability to meet certain operating targets as specified in the acquisition agreement. During the period ended December 31, 2022, the Company made payments of \$nil (December 31, 2021- \$nil). For the three and six month periods ended December 31, 2021-\$nil), and recognized a loss on change in fair value of \$nil (three and six month periods ended December 31, 2021 - \$nil).

The fair value of consideration payable as at December 31, 2022 is summarized below:

|  | \$      |
|--|---------|
| Opening balance, July 1, 2021                    | 9,102   |
| Additions through business combination (Note 20) | 6,543   |
| Payments   | (1,421) |
| Accretion value of earn out (Note 4)             | 798     |
| Gain on change in fair value                     | (2,254) |
| Ending balance, June 30, 2022                    | 12,768  |
| Accretion value of earn out (Note 4)             | 351     |
| Gain on change in fair value                     | (1,931) |
| Ending balance, December 31, 2022                | 11,188  |
| Consideration payable - Current                  | 9,826   |
| Consideration payable - Non-current              | 1,362   |
|  | 11,188  |

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

### 15. Operating facility and loan and derivative assets and liabilities

- (a) Operating facility and loan
- (i) The Company entered into a new loan facility with two banks and drew down the first tranche of \$34,800 (CAD\$45,699) on October 18, 2019. This new loan facility was used to pay down and close all existing loans and to fund part of the purchase of VoIP Innovations LLC. This term facility is repayable over six years on a straight-line basis.

The interest rates charged are based on Prime rate, US Base rate, London Inter-Bank Offered Rate (LIBOR) or Canadian Dollar Offered Rate (CDOR) plus the applicable margin. Under the terms of these term facilities, the Company may convert the loans from variable to a fixed loan. The Company is required to lock in the interest rate on one half of the term loan within three months of each draw down. On January 21, 2020, the Company converted its US Base Rate loan to a one-month LIBOR loan plus the credit spread based on the syndicated loan agreement entered on October 18, 2019. Separately, as required under the agreement, the Company locked in half of the original loan amount by entering a 5-year interest rate credit swap with the two banks for \$8.70 each. On March 28, 2022 the credit agreement was amended and the LIBOR rate was replaced with the Secured Overnight Financing Rate (SOFR). The repayment schedule for the loan has not been impacted by these changes. The balance outstanding against this term loan facility as of December 31, 2022 is \$15,950 (June 30, 2022- \$18,850). As at December 31, 2022, term loan facility balance of \$5,800 (June 30, 2022- \$5,800) is classified as current and \$10,150 (June 30, 2022 - \$13,050) as long-term in the condensed consolidated interim statements of financial position.

- (ii) On March 31, 2021, the Company amended its term loan facility with its lenders and drew down an additional \$52,500 to fund part of the acquisition of StarBlue Inc. At the time of the draw down of the additional amounts, the following amendments were made to the agreement:
  - The provision for additional funding related to VoIP Innovations under the original agreement was no longer necessary and has been cancelled.
  - The swingline facility was converted from CAD \$2,000 to USD \$1,500
  - The revolver facility was converted from CAD \$8,000 to USD \$6,000
  - The debt to equity ratio calculation now allows the Company to offset up to \$10,000 of unrestrained funds against the outstanding amount of the debt.

The interest rates charged continue to be based on Prime rate, US Base rate, London Inter-Bank Offered Rate (LIBOR) or Canadian Dollar Offered Rate (CDOR) plus the applicable margin until March 28, 2022 when the LIBOR rate was replaced with the Secured Overnight Financing Rate (SOFR). The incremental draw is repayable, on a straight-line basis, through quarterly payments of \$2,188 and is due to mature on October 18, 2024. As at December 31, 2022, \$8,750 (June 30, 2022 - \$8,750) of the incremental facility is classified as current and \$28,438 (June 30, 2022 - \$32,812) is classified as long-term in the condensed consolidated interim statements of financial position.

(iii) On March 28, 2022, the Company amended its term loan facility with its lenders and drew down an additional \$45,000 to fund part of the acquisition of NetFortris Corporation. At the time of the draw down of the additional amounts, the following amendments were made to the agreement: The interest rates charged is based on Prime Rate Loans, US Base Rate Loans, US Prime Rate Loans, Secured Overnight Financing Rate (SOFR) or Canadian Dollar Offered Rate (CDOR) plus the applicable margin. The incremental draw is repayable, on a straight-line basis, through quarterly payments of \$1,875 and is due to mature on March 28, 2027. On June 28, 2022, the Company amended its term loan facility with its lenders, the amended repayment for the first twelve quarterly payments of \$788 and \$2,963 thereafter.

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

### 15. Operating facility and loan and derivative assets and liabilities

### (a) Operating facility and loan

As at December 31, 2022, \$3,150 (June 30, 2022-\$3,150) of the incremental facility is classified as current and \$39,487 (June 30, 2022-\$41,063) is classified as long-term in the condensed consolidated interim statements of financial position.

(iv) The Company also had revolving credit facilities which included a committed revolving credit facility for up to \$6,000 and a committed swingline credit facility for up to \$1,500 both of which may be used for general business purposes. On October 19, 2022, the Company drew down \$3,000 from the revolving credit facility and as of December 31, 2022, the amount remains outstanding and is classified as long term in the condensed consolidated interim statements of financial position.

For the three and six month periods ended December 31, 2022, the Company incurred interest costs to service the borrowing facilities in the amount of \$1,363 and \$2,638 (three and six month periods ended December 31, 2021 - \$500 and \$1,036). During the six month period ended December 31, 2022, the Company borrowed \$3,000 (December 31, 2021 - \$nil) in operating facility and loans and repaid \$8,850 (December 31, 2021 - \$7,275).

Under its credit agreements with its lenders, the Company must satisfy certain financial covenants, principally in respect of total funded debt to earnings before interest, taxes and amortization ("EBITDA"), and debt service coverage ratio. As at December 31, 2022 and June 30, 2022 the Company was in compliance with all covenants related to its credit agreements

#### (b) Derivative assets and liabilities

The Company uses derivative financial instruments to hedge its exposure to interest rate risks. All derivative financial instruments are recognized as either assets or liabilities at fair value on the condensed consolidated interim statements of financial position. Upon entering into a hedging arrangement with an intent to apply hedge accounting, the Company formally documents the hedge relationship and designates the instrument for financial reporting purposes as a fair value hedge, a cash flow hedge, or a net investment hedge. When the Company determines that a derivative financial instrument qualifies as a cash flow hedge and is effective, the changes in fair value of the instrument are recorded in accumulated other comprehensive income (loss), net of tax in the condensed consolidated interim statements of financial position and will be reclassified to earnings when the hedge item affects earnings.

On January 21, 2020, the Company converted its US Base Rate loan to a one-month LIBOR loan plus the credit spread based on the syndicated loan agreement entered into on October 18, 2019. Separately, as required under the agreement, the Company locked in half of the original loan amount by entering into a 5-year interest rate credit swap with the two banks for \$8,700 each to manage its exposure to changes in LIBOR-based interest rates. The interest rate swap hedges the variable cash flows associated with the borrowings under the loan facility, effectively providing a fixed rate of interest for five years of the six-year loan term.

The interest rate swap arrangement with two banks became effective on January 31, 2020, with a maturity date of December 31, 2024. The notional amount of the swap agreement at inception was \$17,400 and decreases in line with the term of the loan facility. Effective March 31, 2022, Sangoma US Inc. entered into a fixed rate swap transaction worth \$43,750 over a five year period and terminating on February 28, 2027. As of December 31, 2022, the notional amount of the interest rate swap was \$45,509 (June 30, 2022 – \$51,397). The interest rate swap has a weighted average fixed rate of 1.80% (June 30, 2022 – 1.65%) and have been designated as an effective cash flow hedge and therefore qualifies for hedge accounting.

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

### 15. Operating facility and loan and derivative assets and liabilities

### (b) Derivative assets and liabilities

As at December 31, 2022, the fair value of the interest rate swap assets were valued at current \$1,245 (June 30, 2022-\$649) and non-current \$984 (June 30, 2022-\$700). The current and non-current derivative assets were recorded in the condensed consolidated interim statements of financial position.

For the three and six month periods ended December 31, 2022, the change in fair value of the interest rate swaps, net of tax, was a gain of \$212 and \$649 (three and six month periods ended December 31, 2021 – \$112 and \$151) was recorded in other comprehensive income (loss) in the condensed consolidated interim statements of loss and comprehensive loss. The fair value of interest rate swap is determined based on the market conditions and the terms of the interest rate swap agreement using the discounted cash flow methodology. Any differences between the hedged SOFR rate and the fixed rate are recorded as interest expense on the same period that the related interest is recorded for the loan facility based on the SOFR rate.

#### 16. Contract liabilities

Contract liabilities, which includes deferred revenues, represent the future performance obligations to customers in respect of services or customer activation fees for which consideration has been received upfront and is recognized over the expected term of the customer relationship.

Contract liabilities as at December 31, 2022 and June 30, 2022 are below:

|  | \$       |
|--|----------|
| Opening balance, July 1 , 2021                           | 15,754   |
| Revenue deferred during the period                       | 40,273   |
| Deferred revenue recognized as revenue during the period | (42,625) |
| Additions through business combination (Note 20)         | 1,666    |
| Ending balance, June 30, 2022                            | 15,068   |
| Revenue deferred during the period                       | 17,659   |
| Deferred revenue recognized as revenue during the period | (18,416) |
| Ending balance, December 31, 2022                        | 14,311   |
| Contract liabilities - Current                           | 10,693   |
| Contract liabilities - Non-current                       | 3,618    |
|  | 14,311   |

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

#### 17. Shareholders' equity

### (i) Share capital

The Company's authorized share capital consists of an unlimited number of common shares without par value. As at December 31, 2022 and 2021, the Company's issued and outstanding common shares consist of the following:

|   | Three month periods ended<br>December 31 |            | Six month periods ended<br>December 31 |            |
|---|--|------------|--|------------|
|   |  |            |  |            |
|   | <b>2022</b> 2021                         |            | 2022                                   | 2021       |
|   | #  | #          | #                                      | #          |
| Shares issued and outstanding:                                  |  |            |  |            |
| Outstanding, beginning of the period                            | 22,289,373                               | 19,021,614 | 21,439,632                             | 19,021,642 |
| Shares issued as instalment for shares to be issued             | 981,314                                  | -          | 1,838,458                              | -          |
| Shares purchased and cancelled                                  | (62,622)                                 | -          | (78,822)                               | -          |
| Shares returned from escrow (Note 4)                            | (142,124)                                | -          | (142,124)                              | -          |
| Shares issued upon exercise of options                          | 437                                      | 39,594     | 9,234                                  | 39,594     |
| Rounding of fractional shares in 2021 after share consolidation | -  | -          | -                                      | (28)       |
| Outstanding, end of the period                                  | 23,066,378                               | 19,061,208 | 23,066,378                             | 19,061,208 |

On March 31, 2021, the Company acquired StarBlue Inc. and issued 3,018,685 common shares valued in the amount of \$66,873 as part of the consideration, and 18,456 common shares valued in the amount of \$330 as part of the acquisition costs. Under the terms of the agreement, a further 12,695,600 common shares valued in the amount of \$192,102 are to be issued in instalments commencing on April 1, 2022. On August 3, 2022, 857,144 common shares and on November 8, 2022, 981,314 common shares were issued to StarBlue sellers in accordance with the instalment schedule defined in the share purchase agreement. Following these issuances 10,000,000 common shares remain to be issued and the remaining \$151,315 discounted value of the common shares is recorded as shares to be issued in the condensed consolidated interim statements of changes in shareholders' equity.

During the six month period ended December 31, 2022, a total of 9,234 (December 31, 2021 - 39,594) options were exercised for cash consideration of \$37 (December 31, 2021 - \$346), and the Company recorded a charge of \$20 (December 31, 2021 - \$178) from contributed surplus to share capital.

In the fourth quarter of fiscal 2022, the Company announced its intention to make an NCIB with respect to its Shares. Pursuant to the NCIB, Sangoma may, during the 12-month period commencing June 23, 2022 and ending no later than June 22, 2023, purchase up to 1,071,981 shares, representing 5% of the total number of 21,439,632 Shares outstanding, through the facilities of the TSX, the Nasdaq Global Select Market or alternative Canadian trading systems. Under the term of the Normal Course Issuer Bid ("NCIB"), during the six month period ended December 31, 2022, the Company repurchased a total of 103,122 common shares (December 31, 2021 -nil) at an average price of \$5.42 per share, for total consideration of \$57. During the six month period 73,322 of those common shares were settled and cancelled along with 5,500 common shares that were repurchased in the fourth fiscal quarter of 2022, and the company recorded a total reduction of \$477 (December 31, 2021-nil) in share capital for the value of share repurchased. The remaining 29,800 common shares of the 62,200 common shares repurchased during the second quarter of 2023, were settled and cancelled in January 2023.

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

#### 17. Shareholders' equity

#### (ii) Share based payments

On December 13, 2022, the Corporation's shareholders approved the Plan, which replaces the previous share option plan (the "Legacy Plan"). No further grants will be made under the Legacy Plan.

For the three and six month periods ended December 31, 2022, the Company recognized share-based compensation expense in the amount of \$1,282 and \$2,197 (three and six month periods ended December 31, 2021 - \$2,333 and \$4,452).

### Stock Options

Under the Plan (and previously under the Legacy Plan), employees are periodically granted share options to purchase common shares at prices not less than the market price of the common shares on the day prior to the date of grant or the volume weighted average trading price per share on the TSX during the five trading days immediately preceding the grant date. The fair value of each option grant is estimated at the date of grant using the Black-Scholes option pricing model. Expected volatility is determined by the amount the Corporation's daily share price fluctuated over a period commensurate with the expected life of the options. During the six month period ended December 31, 2022, the Corporation did not grant any options (December 31, 2021 – nil).

The following table shows the movement in the stock option plan:

|                            | Number     | Weighted      |
|----------------------------|------------|---------------|
| Measurement date           | of options | average price |
|                            | #          | \$            |
| Balance, July 1, 2021      | 1,587,310  | 19.55         |
| Granted                    | 285,714    | 18.62         |
| Exercised                  | (39,594)   | (8.80)        |
| Expired                    | (277)      | (9.28)        |
| Forfeited                  | (127,459)  | (18.62)       |
| Balance, December 31 2021  | 1,705,694  | 19.71         |
| Balance, July 1, 2022      | 1,207,908  | 14.02         |
| Exercised                  | (9,234)    | (4.02)        |
| Expired                    | (82,536)   | (16.13)       |
| Forfeited                  | (181,218)  | (17.59)       |
| Balance, December 31, 2022 | 934,920    | 13.24         |

The key assumptions used to fair value the grants were as follows:

|                         | December 31 | December 31 |
|-------------------------|-------------|-------------|
|                         | 2022        | 2021        |
| Share price             | _           | \$18.62     |
| Exercise price          | -           | \$18.62     |
| Expected volatility     | -           | 59.82%      |
| Expected option life    | -           | 5 years     |
| Risk-free interest rate | -           | 0.78%       |

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

#### 17. Shareholders' equity

#### (ii) Share based payments

#### Stock Options

The following table summarizes information about the stock options outstanding and exercisable at the end of each period:

| December 31, 2022 |   |   | December 31 2021      |   |         |   |
|-------------------|---|---|-----------------------|---|---------|---|
| Exercise price    | Number of stock<br>options<br>outstanding | Number of stock options<br>outstanding and<br>exercisable | remaining contractual | Number of stock<br>options<br>outstanding |         | Weighted average<br>remaining contractual<br>life |
| \$3.01 - \$5.00   | 18,018                                    | 18,018  | 0.08                  | 29,906                                    | 20,913  | 0.99  |
| \$5.01 - \$7.00   | 67,338                                    | 53,569  | 0.99                  | 115,409                                   | 65,760  | 1.99  |
| \$7.01-\$9.00     | 241,000                                   | -   | 4.50                  | -   | -       | -   |
| \$9.01 - \$12.00  | 191,479                                   | 100,641   | 2.42                  | 262,641                                   | 86,553  | 3.42  |
| \$12.01-\$15.00   | 55,000                                    | -   | 4.25                  |   |         |   |
| \$15.01-\$18.00   | 178,965                                   | 67,211  | 3.50                  | 239,778                                   | -       | 4.50  |
| \$18.01-\$20.00   | 75,713                                    | 23,667  | 3.67                  | 285,711                                   | -       | 4.73  |
| \$20.01-\$27.00   | 107,407                                   | 47,077  | 3.11                  | 772,249                                   | -       | 4.11  |
|                   | 934,920                                   | 310,183   | 3.30                  | 1,705,694                                 | 173,226 | 3.96  |

#### Share Units

During the three month period ended December 31, 2022, 655,000 were granted (December 31, 2021 - nil). As at December 31, 2022, there were 655,000 RSUs and PSUs issued. (December 31, 2021 - nil). There were no DSUs issued. (December 31, 2021 - nil).

|                                      | PSU     | RSU     | Total   |
|--------------------------------------|---------|---------|---------|
| Awards outstanding July 1, 2022      | -       | -       | -       |
| Awards granted during the period     | 302,500 | 352,500 | 655,000 |
| Awards outstanding December 31, 2022 | 302,500 | 352,500 | 655,000 |

The fair value of each RSU is \$4.20 per share.

The fair value of each of the PSUs tied to non-market based performance targets is \$4.20 per share. The fair value of each of the PSUs tied to market-based performance targets is \$3.69 per share using the Monte Carlo simulation. The key assumptions used in the Monte Carlo simulation are:

|                         | December 31, 2022 | December 31, 2021 |  |
|-------------------------|-------------------|-------------------|--|
|                         |                   |                   |  |
| Share price             | 3.69              | -                 |  |
| Expected volatility     | 60.00%            | -                 |  |
| Time to expirty         | 2.52 years        | -                 |  |
| Risk-free interest rate | 4.08%             | -                 |  |

#### (iii) Loss per share

Both the basic and diluted loss per share have been calculated using the net loss attributable to the shareholders of the Company as the numerator.

|  | Three month periods ended<br>December 31 |            | Six month per<br>Dec |    | riods ended<br>cember 31 |    |            |
|--|--|------------|----------------------|----|--------------------------|----|------------|
|  |  | 2022       | 2021                 |    | 2022                     |    | 2021       |
| Number of shares:  |  |            |                      |    |                          |    |            |
| Weighted average number of shares outstanding                        |  | 22,512,058 | 19,030,708           |    | 23,039,477               |    | 19,026,161 |
| Shares to be issued  |  | 10,000,000 | 12,695,600           |    | 10,000,000               |    | 12,695,600 |
| Weighted average number of shares used in diluted earnings per share |  | 32,512,058 | 31,726,308           |    | 33,039,477               |    | 31,721,761 |
| Net loss for the period  |  | (2,735.00) | (2,477.00)           |    | (4,711.00)               |    | (4,778.00) |
| Loss per share:  |  |            |                      |    |                          |    |            |
| Basic loss per share   | \$                                       | (0.084)    | \$<br>(0.078)        | \$ | (0.143)                  | \$ | (0.151)    |
| Diluted loss per share   | \$                                       | (0.084)    | \$<br>(0.078)        | \$ | (0.143)                  | \$ | (0.151)    |

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

#### 18. Related parties

The Company's related parties include key management personnel and directors. Unless otherwise stated, none of the transactions incorporated special terms and conditions and no guarantees were given or received. Outstanding balances payable are usually settled in cash and relate to director fees.

The Company had incurred no related party transactions and had no outstanding balance with related parties for the three and six month periods ended December 31, 2022 and 2021.

#### 19. Segment disclosures

The Company operates in one operating segment; development, manufacturing, distribution and support of voice and data connectivity components for software-based communication applications. The majority of the Company's assets are located in Canada and the United States of America ("USA"). The Company sells into three major geographic centers: USA, Canada and other foreign countries. The Company has determined that it has a single reportable segment as the Company's decision makers review information on a consolidated basis.

Revenues for group of similar products and services can be summarized for the three and six month periods ended December 31, 2022 and 2021 as follows:

|                | Three month per | Six month periods ended<br>December 31 |         |          |
|----------------|-----------------|--|---------|----------|
|                | Decer           |  |         |          |
|                | 2022            | 2021                                   | 2022    | 2021     |
|                |                 | (Note 2)                               |         | (Note 2) |
|                | \$              | \$                                     | \$      | \$       |
| Products       | 12,604          | 16,447                                 | 28,331  | 32,088   |
| Services       | 49,431          | 36,739                                 | 97,755  | 72,597   |
| Total revenues | 62,035          | 53,186                                 | 126,086 | 104,685  |

The sales, in US dollars, in each of these geographic locations for the three and six month periods ended December 31, 2022 and 2021 as follows:

|                     | Three month per<br>Decer | •        | h periods ended<br>ecember 31 |          |  |
|---------------------|--------------------------|----------|-------------------------------|----------|--|
|                     | 2022                     | 2021     | 2022                          | 2021     |  |
|                     |                          | (Note 2) |                               | (Note 2) |  |
|                     | \$                       | \$       | \$                            | \$       |  |
| USA                 | 57,163                   | 46,998   | 116,845                       | 93,069   |  |
| Canada              | 957                      | 1,562    | 1,965                         | 2,903    |  |
| All other countries | 3,915                    | 4,626    | 7,276                         | 8,713    |  |
| Total revenues      | 62,035                   | 53,186   | 126,086                       | 104,685  |  |

The non-current assets, in US dollars, in each of the geographic locations as at December 31, 2022 and June 30, 2022 are below:

|                          | December 31 | June 30 |
|--------------------------|-------------|---------|
|                          | 2022        | 2022    |
|                          | \$          | \$      |
| Canada                   | 6,578       | 7,000   |
| USA                      | 415,759     | 431,225 |
| Total non-current assets | 422,337     | 438,225 |

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

#### 20. Business combinations

On March 28, 2022, the Company acquired all the shares of NetFortris Corporation. The Company paid an aggregate purchase price of \$64,820, net of a net working capital adjustment of (\$8,942), and comprised of \$50,418 cash consideration, 1,494,536 common shares at a fair value of \$16,801. The Company issued 1,494,536 common shares including 327,241 shares representing a holdback for indemnification purposes on closing of the acquisition. The Company estimates that a further payment of \$6,543 will be paid as part of an earn out that is up to \$12,000 if certain operating targets are met. The Company incurred estimated transaction costs in the amount of \$2,939 which were expensed and included in the condensed consolidated interim statements of loss and comprehensive loss for the three month period ended March 31, 2022. The acquisition has been accounted for using the acquisition method under IFRS 3, Business Combinations.

The following table summarizes the fair value of consideration paid on the acquisition date and the preliminary allocation of the purchase price to the assets and liabilities acquired.

| Consideration  | \$      |
|--|---------|
| Cash consideration on closing                        | 43,868  |
| Net working capital adjustment                       | (8,942) |
| Cash held in escrow for working capital              | 350     |
| Cash held in escrow for telecom taxes                | 3,400   |
| Cash held in escrow for indemnification              | 2,800   |
| Additional consideration for earn out                | 6,543   |
| Common shares issued on closing                      | 13,122  |
| Common shares reserved in escrow for indemnification | 3,679   |
|  | 64,820  |
| Purchase price allocation                            | \$      |
| Cash   | 1,706   |
| Trade receivables                                    | 1,822   |
| Inventories  | 416     |
| Property and equipment                               | 4,172   |
| Right-of-use assets                                  | 3,277   |
| Other current assets                                 | 796     |
| Other non-current assets                             | 370     |
| Deferred income tax asset                            | 11,091  |
| Accounts payable and accrued liabilities             | (9,442) |
| Sales tax payable                                    | (5,506) |
| Contract liabilities                                 | (1,666) |
| Lease obligations on right-of-use assets             | (3,277) |
| Other non-current liabilities                        | (235)   |
| Intangible assets                                    | 29,000  |
| Goodwill   | 32,296  |
|  | 64,820  |

Notes to the condensed consolidated interim financial statements For the three and six month periods ended December 31, 2022 and 2021 (Unaudited in thousands of US dollars, except per share data)

### 21. Subsequent events

There is no subsequent event.

### 22. Authorization of the condensed consolidated interim financial statements

The condensed consolidated interim financial statements were authorized for issuance by the Board of Directors on February 9, 2023.